Compare Firy Inc. (FIRY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Incyte Corporation — how do they compare? Firy Inc. trades at $8.44 (market cap $125.48M), while Incyte Corporation trades at $116.57 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 183.2× Firy Inc.'s market cap, and Incyte Corporation is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| FIRY | INCY | |
|---|---|---|
Market Cap | $125.48M | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $118.52 |
52-Week Low | $2.28 | $67.38 |
Enterprise Value | $69.16M | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $8.04, down 4.74% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. The company recently rebranded and reported Q1 2026 results showing revenue growth to $104.5M but persistent losses with a net margin of -57.48%. Cash flow remains negative at -$86.41M for 2025, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term support at $8, fundamental challenges include deep losses and negative cash flow. Analyst sentiment is mixed with 60% hold ratings. Key risks are profitability timeline and competitive pressure, but rebranding and legal victories may support long-term turnaround if execution improves.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
